About Celiac Disease Drugs Celiac disease is an autoimmune inflammatory disease of the small intestine, which is triggered by intake of gluten from wheat and other sources through our food. Presently, there is no specific drug approved for celiac disease, and the first line of treatment is completely dominated by a gluten-free diet. There are few anti-inflammatory and immunosuppressant drugs and nutritional supplements that are used as off-label therapy in celiac disease. All these off-label therapies are considered as second-line of treatment. Technavio’s analysts forecast the global celiac disease drugs market to grow at a CAGR of 24.22% during the period 2017-2021. Covered in this report The report covers the present scenario and the growth prospects of the global celiac disease drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The market is divided into the following segments based on geography: · Americas · APAC · EMEA... Research Beam Model: Research Beam Product ID: 1673058 3500 USD New
Global Celiac Disease Drugs Market 2017-2021
 
 

Global Celiac Disease Drugs Market 2017-2021

  • Category : Healthcare
  • Published On : June   2017
  • Pages : 76
  • Publisher : Technavio
 
 
 
About Celiac Disease Drugs


Celiac disease is an autoimmune inflammatory disease of the small intestine, which is triggered by intake of gluten from wheat and other sources through our food. Presently, there is no specific drug approved for celiac disease, and the first line of treatment is completely dominated by a gluten-free diet. There are few anti-inflammatory and immunosuppressant drugs and nutritional supplements that are used as off-label therapy in celiac disease. All these off-label therapies are considered as second-line of treatment.


Technavio’s analysts forecast the global celiac disease drugs market to grow at a CAGR of 24.22% during the period 2017-2021.


Covered in this report

The report covers the present scenario and the growth prospects of the global celiac disease drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.


The market is divided into the following segments based on geography:

· Americas

· APAC

· EMEA


Technavio's report, Global Celiac Disease Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.


Key vendors

· F. Hoffmann-La Roche

· Johnson & Johnson

· Merck

· Pfizer



Other prominent vendors

· ADMA Biologics

· Amgen

· Anthera Pharmaceuticals

· Bayer

· Biogen

· BioLineRx

· Biotest

· Bristol-Myers Squibb

· Celgene

· Celimmune

· ImmunogenX

· Immunomedics

· ImmusanT

· Innovate Biopharmaceuticals

· Kedrion Biopharma

· LFB Group

· Novartis

· Shire

· Takeda Pharmaceutical


Market driver

• Prevalence of disease

• For a full, detailed list, view our report


Market challenge

• Long-term sustainability

• For a full, detailed list, view our report


Market trend

• Inorganic growth strategies

• For a full, detailed list, view our report


Key questions answered in this report

• What will the market size be in 2021 and what will the growth rate be?

• What are the key market trends?

• What is driving this market?

• What are the challenges to market growth?

• Who are the key vendors in this market space?

• What are the market opportunities and threats faced by the key vendors?

• What are the strengths and weaknesses of the key vendors?


You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: An overview of celiac disease
PART 06: Market landscape
• Market overview
• Five forces analysis
PART 07: Pipeline landscape
PART 08: Market segmentation by therapy type
• First line of treatment
• Second line of treatment
PART 09: Geographical segmentation
• Celiac disease drugs market in Americas
• Celiac disease drugs market in EMEA
• Celiac disease drugs market in APAC
PART 10: Decision framework
PART 11: Drivers and challenges
• Market drivers
• Market challenges
PART 12: Market trends
• Inorganic growth strategies
• Robust pipeline
PART 13: Vendor landscape
• Competitive scenario
PART 14: Key vendor analysis
• F. Hoffmann-La Roche
• Johnson & Johnson
• Merck
• Pfizer
• Other prominent vendors
PART 15: Appendix
• List of abbreviations

List of Exhibits
Exhibit 01: Stage 1: Initiation process in celiac disease
Exhibit 02: Stage 2: Triggering phase in celiac disease
Exhibit 03: Diagnostic approach for celiac disease
Exhibit 04: Global celiac disease drugs market snapshot
Exhibit 05: Global celiac disease drugs market 2016-2021 ($ millions)
Exhibit 06: Opportunity analysis in global celiac disease treatment market
Exhibit 07: Five forces analysis
Exhibit 08: Pipeline analysis of key molecules for celiac disease
Exhibit 09: Key clinical trials: Celiac disease drugs 2016
Exhibit 10: Segmentation of global celiac disease drugs market by therapy type 2016
Exhibit 11: Global celiac disease first line of treatment market 2016-2021 ($ millions)
Exhibit 12: Various drug classes used in second line of treatment of celiac disease
Exhibit 13: Global celiac disease second line of treatment market 2016-2021 ($ millions)
Exhibit 14: Segmentation of global celiac disease drugs market by geography 2016 and 2021
Exhibit 15: Segmentation of global celiac disease drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 16: Market scenario in Americas
Exhibit 17: Celiac disease drugs market in Americas 2016-2021 ($ millions)
Exhibit 18: Market scenario in EMEA
Exhibit 19: Celiac disease drugs market in EMEA 2016-2021 ($ millions)
Exhibit 20: Market Scenario in APAC
Exhibit 21: Celiac disease drugs market in APAC 2016-2021 ($ millions)
Exhibit 22: Widely consumed foods containing gluten
Exhibit 23: The consumption rate of beer in US 2011-2015
Exhibit 24: Government initiatives by various countries for celiac disease
Exhibit 25: Various symptoms associated with celiac disease
Exhibit 26: Factors affecting long-term sustainability of gluten-free diet
Exhibit 27: Inorganic growth strategies for global celiac disease drugs market
Exhibit 28: Competitive structure analysis of global celiac disease drugs market 2016
Exhibit 29: Competitive factors of global celiac disease drugs market
Exhibit 30: Market penetration of various celiac disease drugs manufacturers worldwide 2016
Exhibit 31: Strategic success factors of companies in global celiac disease drugs market
Exhibit 32: F. Hoffmann-La Roche: Key highlights
Exhibit 33: F. Hoffmann-La Roche: Strength assessment
Exhibit 34: F. Hoffmann-La Roche: Strategy assessment
Exhibit 35: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 36: Johnson & Johnson: Key highlights
Exhibit 37: Johnson & Johnson: Strength assessment
Exhibit 38: Johnson & Johnson: Strategy assessment
Exhibit 39: Johnson & Johnson: Opportunity assessment
Exhibit 40: Merck: Key highlights
Exhibit 41: Merck: Strength assessment
Exhibit 42: Merck Strategy assessment
Exhibit 43: Merck: Opportunity assessment
Exhibit 44: Pfizer: Key highlights
Exhibit 45: Pfizer: Strength assessment
Exhibit 46: Pfizer: Strategy assessment
Exhibit 47: Pfizer: Opportunity assessment

PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter

 
 
REQUEST SAMPLE    ASK FOR DISCOUNT